MGMR, a next-generation carbon nanotube, solves drug development challenges

BioPact’s MGMR (Medical Grade Molecular Rebar) offers a safe and scalable nanoparticle platform for controlled and targeted delivery of a wide range of therapeutics.

Go to the profile of BioPact
Oct 25, 2016
Page of
Go to the profile of BioPact


BioPact’s innovative drug delivery platform, Medical Grade Molecular Rebar (MGMR™), comprises discrete, individualized, pure, length-controlled, surface-functionalized carbon nanotubes (CNT). By utilizing our patented technology, drug developers can solve challenges in many arenas such as: controlled release, targeted delivery, transdermal delivery, toxicity, physiological instability, intracellular delivery, or crossing the blood-brain barrier. The unique properties of these tubes overcome the limitations of traditional CNT which are impure, tangled bundles of carbon. MGMR can be internally loaded with large and/or small molecules, regardless of chemistries, while the exterior of the tube is available for functionalization with bioactive agents to create a targeted drug delivery system.

No comments yet.